Development Core

开发核心

基本信息

  • 批准号:
    10477366
  • 负责人:
  • 金额:
    $ 10.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-07 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT The goal of the Developmental Core is to enhance the research training, leadership capacity and professional networking for junior Kenyan and Ugandan health care professionals who are interested in addressing research questions regarding HIV-associated malignancies. This U54 renewal application continues to focus on strengthening research capacity related to human papillomavirus (HPV) and cervical cancer in HIV-infected women of East Africa. In Kenya, coordination will be through the Academic Model Providing Access to Healthcare (AMPATH) partnership which consists of a collaborative network of North American academic medical schools, Moi University and Moi Teaching and Referral Hospital. In Uganda, coordination will be with the International Epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration and Makerere University that has fostered collaborative research mentoring through participation in the Afya Bora Consortium; an interprofessional program fostering global health leadership. This Core brings together our collective expertise to rapidly advance research capacity focused on HIV-associated malignancies and to help develop the next generation of Kenyan and Ugandan research leaders through the following Specific Aims: Specific Aim 1: To leverage the current and future U54 Project cohort data to enhance the translational and population-based HIV/AIDS and HIV-Associated Malignancy peer-reviewed research in East Africa. Through a competitive application process, we will award 4-6 pilot projects each year. Each mentee will be matched to a primary scientific mentor, assigned a designated site mentor, and supervised by a Research Advisory Committee (RAC) consisting of team members with relevant professional and technical expertise. Mentoring will include research methodologies, implementation, grant writing skills, budgeting and financial management. Mentees are expected to submit first-author publications and an external grant application. Specific Aim 2: To establish a mentorship and leadership development program to promote research in HIV-associated malignancies for Kenyan and Ugandan healthcare professionals. There are unique skills developed by researchers when their study populations are HIV-infected and/or have cancer, which are chronic diseases often associated with poor prognoses and long-term care. Training modules and professional development tools from the Afya Bora Consortium will be modified to address these challenges. Systematic evaluations will inform the development of sustainable mentorship and leadership development programs. Specific Aim 3: To develop sustainable professional networking and collaborative research mechanisms that unite Kenyan and Ugandan healthcare professionals and trainees. Monthly seminars will strengthen this newly established collaboration and showcase inter-related and complementary research projects. Junior trainees will have an opportunity to apply for Travel Awards so they may present at scientific conferences, thereby expanding their professional network and gaining recognition in their field.
抽象的 发展核心的目标是增强研究培训,领导能力和专业 有兴趣解决研究的初级肯尼亚和乌干达医疗保健专业人员的网络 有关艾滋病毒相关的恶性肿瘤的问题。此U54更新应用程序继续关注 增强与人乳头瘤病毒(HPV)和宫颈癌有关的研究能力 东非的妇女。在肯尼亚,协调将通过提供医疗保健的学术模式 (Ampath)合作伙伴关系由北美学术医学院的合作网络组成, MOI大学和MOI教学和推荐医院。在乌干达,将与国际 评估AIDS(IEDEA)合作和Makerere大学的流行病学数据库 通过参加Afya Bora财团的协作研究指导;专业计划 促进全球卫生领导力。该核心汇集了我们的集体专业知识,以快速提高研究 侧重于艾滋病毒相关的恶性肿瘤的能力,并帮助发展下一代肯尼亚和 乌干达研究负责人通过以下具体目标: 特定目的1:利用当前和未来的U54项目队列数据来增强翻译 东非和基于人群的艾滋病毒/艾滋病和艾滋病毒相关的恶性同行评审研究。 通过竞争性申请流程,我们每年将授予4-6个试点项目。每个受训者将是 与主要科学导师相匹配,分配了指定的现场导师,并通过研究监督 咨询委员会(RAC)由具有相关专业和技术专长的团队成员组成。 指导将包括研究方法,实施,授予写作技巧,预算和财务 管理。预计受训者将提交第一职业出版物和外部赠款申请。 具体目标2:建立指导和领导力发展计划,以促进研究 肯尼亚和乌干达医疗保健专业人员与HIV相关的恶性肿瘤。有独特的技能 当研究人员的研究人群感染HIV和/或患有癌症时,由研究人员开发 疾病通常与预后不良和长期护理有关。培训模块和专业人士 AFYA BORA财团的开发工具将被修改以应对这些挑战。系统 评估将为可持续指导和领导力发展计划的发展提供信息。 特定目标3:开发可持续的专业网络和协作研究机制 肯尼亚和乌干达医疗保健专业人员和学员团结一致。每月研讨会将加强 这个新建立的合作和展示了相关和互补的研究项目。初级 学员将有机会申请旅行奖,因此他们可能会参加科学会议, 从而扩大他们的专业网络并在其领域获得认可。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Barry Rosen其他文献

Barry Rosen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Barry Rosen', 18)}}的其他基金

Development Core
开发核心
  • 批准号:
    10084052
  • 财政年份:
    2020
  • 资助金额:
    $ 10.72万
  • 项目类别:
Development Core
开发核心
  • 批准号:
    10256041
  • 财政年份:
    2020
  • 资助金额:
    $ 10.72万
  • 项目类别:

相似海外基金

Tanzania AIDS Malignancies Training and Research International Program (TAMTRP)
坦桑尼亚艾滋病恶性肿瘤培训和研究国际计划 (TAMTRP)
  • 批准号:
    10650673
  • 财政年份:
    2022
  • 资助金额:
    $ 10.72万
  • 项目类别:
Stress keratin 17 and CD4/8 ratio as prognostic markers in HIV-related anogenital squamous cell precancers and cancers (Biospecimens/Biocohort)
应激角蛋白 17 和 CD4/8 比率作为 HIV 相关肛门生殖器鳞状细胞癌前病变和癌症的预后标志物 (Biospecimens/Biocohort)
  • 批准号:
    10620051
  • 财政年份:
    2022
  • 资助金额:
    $ 10.72万
  • 项目类别:
AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
  • 批准号:
    10405562
  • 财政年份:
    2022
  • 资助金额:
    $ 10.72万
  • 项目类别:
Defining the genomic and microenvironmental features of diffuse large B cell lymphoma in HIV + patients (Biospecimens/Biocohort)
定义 HIV 患者弥漫性大 B 细胞淋巴瘤的基因组和微环境特征(生物样本/生物队列)
  • 批准号:
    10619709
  • 财政年份:
    2022
  • 资助金额:
    $ 10.72万
  • 项目类别:
(PQ6) Mesenchymal stem cell based and immunocompetent mouse models of HIV/AIDS KSHV-driven sarcomagenesis
(PQ6) 基于间充质干细胞和免疫活性的 HIV/AIDS 小鼠模型 KSHV 驱动的肉瘤发生
  • 批准号:
    10228426
  • 财政年份:
    2021
  • 资助金额:
    $ 10.72万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了